Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding dries up.

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic Gets $63 Million US Government Order for Small Pox, Mpox Vaccine (Reuters) - Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional ...

The WHO’s declaration of an emergency has caused Bavarian Nordic’s shares to jump over 40%. The company's shares are up 51% since the start of the year, with its market cap at $3.28 billion.

Fortune Europe Inside Bavarian Nordic: The $3.3 billion Danish vaccine maker with the world's only cure for mpox Forbes Mpox Vaccine Maker’s Shares Continue Rising As Concern Over Virus Outbreak ...

Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. Skip to Main Content.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Looking ahead to the rest of the year, Bavarian Nordic aims to grow earnings some 26% to 30% over that same span. As for what could be next in the company’s travel health portfolio, Bavarian ...

Aug 17 (Reuters) - Danish biotech firm Bavarian Nordic , opens new tab said on Saturday it plans to ramp up production of its mpox vaccine and work with international health organisations to ...

Bavarian Nordic is also sponsoring a trial (NCT06549530) of MVA-BN in children aged 2-11 years, with topline data anticipated in Q3 2025. Jynneos is the only non-replicating mpox vaccine approved ...